The startup develops psychedelic-inspired therapeutics derived from plants and fungi to treat neuropsychiatric conditions. Their platform focuses on the research and delivery of these therapeutics and nutraceuticals, enabling healthcare providers to improve patient outcomes in mental health and wellness.
Funding
$4.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for neuroinflammatory and neuropsychiatric disorders often have limited efficacy and significant side effects. Traditional drug discovery methods are costly and time-consuming, hindering the development of novel therapeutic interventions.
Solution
Huxley Health is a biotechnology company focused on developing psychedelic-inspired therapeutics for nervous system disorders. The company leverages a targeted, capital-efficient research approach, enhanced by AI, to identify and develop novel compounds and formulations. By partnering with leading research institutions, Huxley Health aims to accelerate the discovery and delivery of groundbreaking therapies for neuroinflammatory and neuropsychiatric conditions. Their approach focuses on maximizing R&D efficiency while reducing traditional costs associated with drug development.
Target Audience
The primary target audience includes individuals suffering from neuroinflammatory and neuropsychiatric disorders, as well as healthcare providers seeking innovative treatment options.
Features
- AI-enhanced drug development platform for screening billions of compounds
- Focus on psychedelic-inspired therapeutics derived from plants and fungi
- Robust IP portfolio protecting novel compounds and formulations
- Partnerships with world-leading research institutions
- Targeted approach to neuroinflammatory and neuropsychiatric disorders